Market revenue in 2023 | USD 11,942.4 million |
Market revenue in 2030 | USD 14,933.7 million |
Growth rate | 3.2% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 62.2% in 2023. Horizon Databook has segmented the North America inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the market in 2022 due to presence of key players in the market, initiatives undertaken by regulatory bodies for funding R&D, increased awareness about the disease, and emerging use of novel treatments & biosimilars.
This can significantly improve availability of therapeutics. Furthermore, increase in manufacturing capacities to expand supply of new drugs is expected to fuel market growth. For instance, in June 2020, Takeda Pharmaceutical Company Ltd. received FDA approval to manufacture Entyvio (vedolizumab) in its manufacturing facility at Brooklyn Park, Minnesota.
Presence of a robust pipeline of drugs and increase in the number of clinical trials of drug candidates in the region are among the major factors expected to boost market growth in North America. Moreover, increase in prevalence of IBD in the region is anticipated to boost market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America inflammatory bowel disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account